A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis

P. Joy Ho, Ashish Bajel, Kate Burbury, Lindsay Dunlop, Simon Durrant, Cecily Forsyth, Andrew C. Perkins, David Ross

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Ruxolitinib is a dual janus kinase 1 (JAK1)/JAK2 inhibitor used to treat splenomegaly and symptoms associated with myelofibrosis (MF). Current therapeutic options for symptomatic MF include supportive care, myelosuppressive therapy (such as hydroxycarbamide) and janus kinase (JAK) inhibitors (in particular ruxolitinib). Allogeneic stem cell transplantation remains the only potentially curative treatment for MF, and younger transplant-eligible patients should still be considered for allogeneic stem cell transplantation; however, this is applicable only to a small proportion of patients. There is now increasing and extensive experience of the efficacy and safety of ruxolitinib in MF, both in clinical trials and in ‘real-world’ practice. The drug has been shown to be of benefit in intermediate-1 risk patients with symptomatic splenomegaly or other MF-related symptoms, and higher risk disease. Optimal use of the drug is required to maximise clinical benefit, requiring an understanding of the balance between dose-dependent responses and dose-limiting toxicities. There is also increasing experience in the use of ruxolitinib in the pre-transplantation setting. This paper aims to utilise several ‘real-life’ cases to illustrate several strategies that may help to optimise clinical practice.

LanguageEnglish
Pages262-268
Number of pages7
JournalInternal Medicine Journal
Volume47
Issue number3
DOIs
Publication statusPublished - 1 Mar 2017

Keywords

  • drug-related side effects and adverse reactions
  • janus kinases
  • primary myelofibrosis
  • prognosis
  • ruxolitinib

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Ho, P. Joy ; Bajel, Ashish ; Burbury, Kate ; Dunlop, Lindsay ; Durrant, Simon ; Forsyth, Cecily ; Perkins, Andrew C. ; Ross, David. / A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis. In: Internal Medicine Journal. 2017 ; Vol. 47, No. 3. pp. 262-268.
@article{d0dbb9e2817a4d9e92908e8e443c9f14,
title = "A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis",
abstract = "Ruxolitinib is a dual janus kinase 1 (JAK1)/JAK2 inhibitor used to treat splenomegaly and symptoms associated with myelofibrosis (MF). Current therapeutic options for symptomatic MF include supportive care, myelosuppressive therapy (such as hydroxycarbamide) and janus kinase (JAK) inhibitors (in particular ruxolitinib). Allogeneic stem cell transplantation remains the only potentially curative treatment for MF, and younger transplant-eligible patients should still be considered for allogeneic stem cell transplantation; however, this is applicable only to a small proportion of patients. There is now increasing and extensive experience of the efficacy and safety of ruxolitinib in MF, both in clinical trials and in ‘real-world’ practice. The drug has been shown to be of benefit in intermediate-1 risk patients with symptomatic splenomegaly or other MF-related symptoms, and higher risk disease. Optimal use of the drug is required to maximise clinical benefit, requiring an understanding of the balance between dose-dependent responses and dose-limiting toxicities. There is also increasing experience in the use of ruxolitinib in the pre-transplantation setting. This paper aims to utilise several ‘real-life’ cases to illustrate several strategies that may help to optimise clinical practice.",
keywords = "drug-related side effects and adverse reactions, janus kinases, primary myelofibrosis, prognosis, ruxolitinib",
author = "Ho, {P. Joy} and Ashish Bajel and Kate Burbury and Lindsay Dunlop and Simon Durrant and Cecily Forsyth and Perkins, {Andrew C.} and David Ross",
year = "2017",
month = "3",
day = "1",
doi = "10.1111/imj.13341",
language = "English",
volume = "47",
pages = "262--268",
journal = "Australian and New Zealand Journal of Medicine",
issn = "1444-0903",
publisher = "Wiley-Blackwell",
number = "3",

}

A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis. / Ho, P. Joy; Bajel, Ashish; Burbury, Kate; Dunlop, Lindsay; Durrant, Simon; Forsyth, Cecily; Perkins, Andrew C.; Ross, David.

In: Internal Medicine Journal, Vol. 47, No. 3, 01.03.2017, p. 262-268.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis

AU - Ho, P. Joy

AU - Bajel, Ashish

AU - Burbury, Kate

AU - Dunlop, Lindsay

AU - Durrant, Simon

AU - Forsyth, Cecily

AU - Perkins, Andrew C.

AU - Ross, David

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Ruxolitinib is a dual janus kinase 1 (JAK1)/JAK2 inhibitor used to treat splenomegaly and symptoms associated with myelofibrosis (MF). Current therapeutic options for symptomatic MF include supportive care, myelosuppressive therapy (such as hydroxycarbamide) and janus kinase (JAK) inhibitors (in particular ruxolitinib). Allogeneic stem cell transplantation remains the only potentially curative treatment for MF, and younger transplant-eligible patients should still be considered for allogeneic stem cell transplantation; however, this is applicable only to a small proportion of patients. There is now increasing and extensive experience of the efficacy and safety of ruxolitinib in MF, both in clinical trials and in ‘real-world’ practice. The drug has been shown to be of benefit in intermediate-1 risk patients with symptomatic splenomegaly or other MF-related symptoms, and higher risk disease. Optimal use of the drug is required to maximise clinical benefit, requiring an understanding of the balance between dose-dependent responses and dose-limiting toxicities. There is also increasing experience in the use of ruxolitinib in the pre-transplantation setting. This paper aims to utilise several ‘real-life’ cases to illustrate several strategies that may help to optimise clinical practice.

AB - Ruxolitinib is a dual janus kinase 1 (JAK1)/JAK2 inhibitor used to treat splenomegaly and symptoms associated with myelofibrosis (MF). Current therapeutic options for symptomatic MF include supportive care, myelosuppressive therapy (such as hydroxycarbamide) and janus kinase (JAK) inhibitors (in particular ruxolitinib). Allogeneic stem cell transplantation remains the only potentially curative treatment for MF, and younger transplant-eligible patients should still be considered for allogeneic stem cell transplantation; however, this is applicable only to a small proportion of patients. There is now increasing and extensive experience of the efficacy and safety of ruxolitinib in MF, both in clinical trials and in ‘real-world’ practice. The drug has been shown to be of benefit in intermediate-1 risk patients with symptomatic splenomegaly or other MF-related symptoms, and higher risk disease. Optimal use of the drug is required to maximise clinical benefit, requiring an understanding of the balance between dose-dependent responses and dose-limiting toxicities. There is also increasing experience in the use of ruxolitinib in the pre-transplantation setting. This paper aims to utilise several ‘real-life’ cases to illustrate several strategies that may help to optimise clinical practice.

KW - drug-related side effects and adverse reactions

KW - janus kinases

KW - primary myelofibrosis

KW - prognosis

KW - ruxolitinib

UR - http://www.scopus.com/inward/record.url?scp=85014398257&partnerID=8YFLogxK

U2 - 10.1111/imj.13341

DO - 10.1111/imj.13341

M3 - Article

VL - 47

SP - 262

EP - 268

JO - Australian and New Zealand Journal of Medicine

T2 - Australian and New Zealand Journal of Medicine

JF - Australian and New Zealand Journal of Medicine

SN - 1444-0903

IS - 3

ER -